Apotex Health: this analyst just raised his price target

Monday at 10:25am AST · November 16, 2026 3 min read
Last updated on November 16, 2026 at 10:25am AST

RBC Capital Markets analyst Douglas Miehm raised his target for Apotex Health (Apotex Health Stock Quote, Chart, News, Analysts, Financials TSXV:APTX) to $46.00 from $43.00 following stronger-than-expected second-quarter results and an increase in the company’s fiscal 2027 financial guidance.

On Nov. 13, Miehm maintained his “Outperform” rating on the Toronto-based pharmaceutical company, which reported results on Nov. 12.

“Apotex delivered another strong quarter,” Miehm said. “Ex-VLLP revenue of $853-million (up 5 per cent year-over-year) was 3 per cent ahead of cons. and adj. EBITDA of $280-million beat cons. by 23 per cent, driven by strong GMs of 52 per cent (vs. 48 per cent estimated).”

Revenue excluding the U.S. contribution from its volume-limited licence product (VLLP), generic Revlimid, increased to $853-million from $813-million a year earlier. Reported revenue increased 1%, reflecting the loss of contributions from the agreement in the prior-year period. Adjusted EBITDA excluding VLLP increased 19% to $280-million, while the margin improved to 33% from 29% a year earlier.

Canadian revenue increased approximately 14% to $413-million, supported by new product launches, including Apo-Semaglutide. Miehm said the generic semaglutide product has established a significant position in the Canadian market. “Apo-Semaglutide reached 21 per cent of the total CDN semaglutide market, with the category expanding 19 per cent year-over-year,” he said.

Apotex reported that revenue from its conventional generics business, excluding VLLP, increased 11% to $410-million, supported by new product introductions. Specialty generics revenue declined 8% to $287-million, reflecting increased competition following the expiration of exclusivity for certain products and a temporary pause in U.S. ophthalmic product sales. Revenue from brands and biosimilars increased 18% to $156-million, partly reflecting the addition of pharmaceutical products acquired from Cumberland Pharmaceuticals.

The company launched approximately 60 products during the first half of fiscal 2027, with 70% being first-to-market products.

Following the results, Apotex increased its fiscal 2027 revenue growth guidance, excluding VLLP, to between 9% and 10%, from its previous forecast of 7% to 8%. It also raised its expected Adjusted EBITDA margin to approximately 31% from 30%.

The analyst said the revised outlook suggests that improvements in the company’s operations are becoming more sustainable.

“FQ4 competitive normalization and spend timing are watch items, but we view the full-year margin upgrade as reflecting structural progress on productivity and mix,” he said.

Apotex reported second-quarter net income of $101-million, compared with $83-million a year earlier. Diluted earnings per share were $0.41, down from $0.43, reflecting an increase in shares outstanding following its initial public offering. The company ended September with net debt of approximately $2.27-billion and a net debt leverage ratio of 2.3 times.

-30-

Author photo

Rod Weatherbie

Writer

Rod Weatherbie is a journalist based in Prince Edward Island. Since 2004, he has written extensively about the Canadian property and casualty insurance landscape. He was also a founder and contributing editor for a Toronto-based arts website and a PEI-based food magazine. His fiction and poetry have been featured in The Fiddlehead, The Antigonish Review, and Juniper.

displaying rededs